FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

As the United States market grapples with mixed performances across major indices, with the S&P 500 and Nasdaq showing slight gains while the Dow Jones Industrial Average tumbles, investors are ...

Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy ...

The United States market has remained flat over the last week, though it has experienced a 5.7% rise over the past 12 months, ...

DelveInsight's "TRYVIO/JERAYGO Market Size, Forecast, and Market Insight Report" highlights the details around TRYVIO/JERAYGO ...

Factors driving the market include rising disease prevalence, innovative therapies, and gene-based treatment breakthroughs. Key players like H Lundbe ...

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February ...